Prophylaxis of venous thromboembolism in stroke patients.

abstract：:Factor (F) VIII is a large gene located near the terminus of the long arm of the X chromosome. It contains 26 exons that code for a signal peptide and a 2332 amino acid polypeptide with three different types of domains, namely A1-A2-B-A3-C1-C2. The A domains are homologous with each other and those of ceruloplasmin; s...

journal_title：Seminars in thrombosis and hemostasis

authors： Thompson AR

更新日期：2003-02-01 00:00:00

abstract：:Approximately 5 to 7% of patients with hemophilia A have inhibitory antibodies to factor (F) VIII, which increases to approximately 13% in patients with severe disease. The strongest determinant of the risk of inhibitor development identified is the type of mutation in the FVIII gene that gives rise to the disease. Ho...

journal_title：Seminars in thrombosis and hemostasis

authors： Lee CA,Lillicrap D,Astermark J

更新日期：2006-06-01 00:00:00

abstract：:Recently it was reported that chorionic villous hemorrhage (CVH) had a significant association with retroplacental hemorrhage (RPH). In this study, to determine whether CVH has a correlation with RPH or intervillous thrombosis (IVT), placentas associated with CVH were clinico-histopathologically investigated and compa...

journal_title：Seminars in thrombosis and hemostasis

authors： Soma H,Watanabe Y,Osawa H,Hata T

更新日期：1998-01-01 00:00:00

abstract：:The long-term success rate of coronary angioplasty is only 50 to 70% due to restenosis. The pathophysiologic mechanism of this event is mainly mediated by smooth muscle cell proliferation. To some extent, it can be inhibited by heparin. The introduction of LMWHs allows for prophylaxis against restenosis on an outpatie...

journal_title：Seminars in thrombosis and hemostasis

authors： Lojewski B,Bacher P,Iqbal O,Walenga JM,Hoppensteadt DA,Leya F,Fareed J

更新日期：1993-01-01 00:00:00

abstract：:Current guidelines for venous thromboembolism (VTE) primary prophylaxis are based on randomized clinical trials that exclude subjects at a potentially high bleeding risk. Thus no specific recommendation/algorithm for pharmacological prophylaxis in patients with thrombocytopenia and/or platelet dysfunction is available...

journal_title：Seminars in thrombosis and hemostasis

authors： Tufano A,Guida A,Di Minno MN,Prisco D,Cerbone AM,Di Minno G

更新日期：2011-04-01 00:00:00

abstract：:Epidemiological and laboratory studies performed in the last decades have changed our understanding of coagulopathy in cirrhosis, from a condition at increased risk of hemorrhagic events to one at higher thrombotic risk. However, it is not clear whether the decrease in factors that promote (except factor [F] VIII) ver...

journal_title：Seminars in thrombosis and hemostasis

authors： Lebreton A,Sinegre T,Lecompte T,Talon L,Abergel A,Lisman T

更新日期：2020-09-01 00:00:00

abstract：:Patients with unprovoked venous thromboembolism (VTE) may harbor occult cancer. Whether an extensive diagnostic work-up for cancer has additional value over a more limited screening for detection of underlying malignancy in these patients is controversial. We performed a randomized multicenter trial to assess if in pa...

journal_title：Seminars in thrombosis and hemostasis

authors： Prandoni P,Bernardi E,Valle FD,Visonà A,Tropeano PF,Bova C,Bucherini E,Islam MS,Piccioli A

更新日期：2016-11-01 00:00:00

abstract：:There exist multiple clinical conditions, situations, and diseases in which persons appear to be at increased risk for thromboembolic phenomena, such as venous thrombosis and pulmonary embolus. Within this group of conditions, situations, or diseases, some are more clearly linked to thromboembolism that others. Simila...

journal_title：Seminars in thrombosis and hemostasis

authors： Kitchens CS

更新日期：1985-07-01 00:00:00

abstract：:Platelet-lowering therapy in myeloproliferative disorders includes cytostatic drugs, mainly hydroxyurea, interferon alpha, and anagrelide. Anagrelide is the latest addition to the therapeutic arsenal, and the basis for its use is reviewed. The platelet-lowering efficacy is 70 to 80% in essential thrombocythemia, and t...

journal_title：Seminars in thrombosis and hemostasis

authors： Birgegard G

更新日期：2006-04-01 00:00:00

abstract：:In order to obtain a global assessment of circulating clopidogrel-related products and of the excretion of the drug, the pharmacokinetic behavior and the excretion balance of 14C radioactivity following the administration of a single dose of 75 mg of 14C-labeled clopidogrel were compared in 6 clopidogrel-free healthy ...

journal_title：Seminars in thrombosis and hemostasis

authors： Lins R,Broekhuysen J,Necciari J,Deroubaix X

更新日期：1999-01-01 00:00:00

abstract：:Prophylactic treatment from ages 2 to 18 years could prevent the development of hemophilic arthropathy if the concentration of the patient's deficient factor is kept from falling below 1% of normal. Early treatment is of paramount importance because the immature skeleton is very sensitive to the complications of hemop...

journal_title：Seminars in thrombosis and hemostasis

authors： Rodriguez-Merchan EC

更新日期：2003-02-01 00:00:00

abstract：:Available data suggest that elevated triglyceride levels in plasma, associated with increased VLDL or chylomicron remnants, are associated with premature coronary artery atherosclerosis. Whether this is a direct effect or as a result of the association of hypertriglyceridemia with decreased HDL as well as decreased LD...

journal_title：Seminars in thrombosis and hemostasis

authors： Schaefer EJ,McNamara JR,Genest J Jr,Ordovas JM

更新日期：1988-04-01 00:00:00

abstract：:This epilogue represents a final summary of the issues discussed and highlighted at the International Summit on Differentiation of Low Molecular Weight Heparins (LMWHs). International scientists and physicians presented and discussed the physicochemical differences between LMWHs, and concluded that different productio...

journal_title：Seminars in thrombosis and hemostasis

authors： Fareed J,Haas S,Sasahar A

更新日期：1999-01-01 00:00:00

abstract：:Immunoblotting techniques for the qualitative and quantitative analysis of FXII, PK, and HMWK in whole plasma are presented. Sensitive, specific, and quantitative immunodetection of FXII and PK can be achieved by developing the blots with polyclonal antiserum followed by radiolabeled FXII or PK, respectively. This app...

journal_title：Seminars in thrombosis and hemostasis

authors： Lämmle B,Berrettini M,Griffin JH

更新日期：1987-01-01 00:00:00

abstract：:The polymorphism in the composition and actions of heparin and the parallel complexity of the thrombotic process have led to the design of a cautious, methodical, and pragmatic program of development of the first low molecular heparin fraction presently available in France (CY 216). The main idea was always to present...

journal_title：Seminars in thrombosis and hemostasis

authors： Toulemonde F

更新日期：1989-10-01 00:00:00

abstract：:Recombinant thrombolytic peptides are mainly represented by recombinant forms of tissue plasminogen activator (t-PA), a proteolytic enzyme that catalyzes the conversion of plasminogen into active plasmin, which then functions to dissolve clots. The three clinically relevant recombinant thrombolytic peptides are altepl...

journal_title：Seminars in thrombosis and hemostasis

authors： Campbell J,Hilleman D

更新日期：2010-07-01 00:00:00

abstract：:The contribution of platelet dysfunction to the impaired hemostasis after cardiac surgery remains to be established, because there is no sensitive method to assess platelet function. Measurement of the shear-induced pathway of platelet function, an important mechanism in inducing hemostasis, became possible by a novel...

journal_title：Seminars in thrombosis and hemostasis

authors： Tabuchi N,Tigchelaar I,van Oeveren W

更新日期：1995-01-01 00:00:00

abstract：:In severe infection and sepsis, activation of coagulation frequently occurs, which contributes to the development of multiple organ dysfunction. Factor V Leiden is a relatively common mutation resulting in a mild prohemostatic state and consequently with an increased tendency to develop thrombosis. Hypothetically, pat...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M,Schouten M,van't Veer C,van der Poll T

更新日期：2011-11-01 00:00:00

abstract：INTRODUCTION:The aim of this study was to evaluate the genetic variability of selected single nucleotide polymorphisms (SNPs) within GAS6 and PEAR1 genes and explore the association between selected SNPs and risk for fetal loss in women with sticky platelet syndrome (SPS). MATERIALS AND METHODS:We examined 23 female p...

journal_title：Seminars in thrombosis and hemostasis

authors： Sokol J,Biringer K,Skerenova M,Stasko J,Kubisz P,Danko J

更新日期：2015-04-01 00:00:00

abstract：:The increase of circulating tissue factor pathway inhibitor (TFPI) in plasma by heparins is thought to contribute to their overall antithrombotic activity. In a clinical study in healthy volunteers, we recently found that the specific potency of a heparin to mobilize TFPI from the vessel wall increases with its molecu...

journal_title：Seminars in thrombosis and hemostasis

authors： Alban S

更新日期：2001-10-01 00:00:00

abstract：:We investigated the protective effects of DX-9065a, an orally active, newly synthesized, and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation (DIC) in rats. Experimental DIC was induced by a 4 hour sustained infusion of thromboplastin at a dose of 2.5 mg/kg. The rats were or...

journal_title：Seminars in thrombosis and hemostasis

authors： Yamazaki M,Asakura H,Aoshima K,Saito M,Jokaji H,Uotani C,Kumabashiri I,Morishita E,Ikeda T,Matsuda T

更新日期：1996-01-01 00:00:00

abstract：: ...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ

更新日期：2019-02-01 00:00:00

abstract：:Site-directed thrombin inhibitors are being currently assessed clinically for their antithrombotic efficacy. Although these agents are claimed to be specific and direct thrombin inhibitors, their mechanism of inhibition varies. The objective of these studies was to compare four such agents in in vitro systems and to a...

journal_title：Seminars in thrombosis and hemostasis

authors： Callas DD,Hoppensteadt D,Fareed J

更新日期：1995-01-01 00:00:00

abstract：:Severe factor XI (FXI) deficiency is an injury-related bleeding disorder common in Ashkenazi Jews and rare worldwide. In the past two decades, more than 180 mutations in the FXI gene have been reported in patients with FXI deficiency, five of which show a founder effect (Cys38Arg, Gln88Stop, Cys128Stop, Glu117stop, an...

journal_title：Seminars in thrombosis and hemostasis

authors： Duga S,Salomon O

更新日期：2009-06-01 00:00:00

abstract：:The selection of treatment for patients with polycythemia vera (PV) still is the subject of much discussion among hematologists. It is emphasized that important physiologic and pathogenic components of the illness relate not only to the erythroid cell, but also to the megakaryocyte. Both play essential roles in causin...

journal_title：Seminars in thrombosis and hemostasis

authors： Silver RT

更新日期：2006-06-01 00:00:00

abstract：:Low-molecular-weight heparins (LMWHs) are now universally accepted as drugs of choice for postsurgical prophylaxis and treatment of deep vein thrombosis (DVT). Currently, these agents are also being developed for the treatment of various cardiovascular conditions. Because of manufacturing differences, each of the LMWH...

journal_title：Seminars in thrombosis and hemostasis

authors： Fareed J,Ma Q,Florian M,Maddineni J,Iqbal O,Hoppensteadt DA,Bick RL

更新日期：2004-02-01 00:00:00

abstract：:With the strides being made in the European, Canadian, and American prospective studies of von Willebrand disease (VWD) genotype and phenotype, genetics is increasingly playing a key role in the classification, understanding, and management of VWD. It is anticipated that as gene sequencing becomes easier and more comm...

journal_title：Seminars in thrombosis and hemostasis

authors： Novelli EM,Ragni MV

更新日期：2008-09-01 00:00:00

abstract：:Through in depth studies, the biochemical pathways of hemostasis-related systems have been elucidated in terms of well-defined molecular mechanisms. The interrelationships of coagulation, fibrinolytic, kallikrein-kinin, platelets, prostaglandins, blood vessel, and complement systems are now well understood. Methods ar...

journal_title：Seminars in thrombosis and hemostasis

authors： Fareed J,Walenga JM,Bick RL,Bermes EJ Jr,Messmore HL Jr

更新日期：1983-10-01 00:00:00

abstract：:The increasing use of antiplatelet therapy, particularly aspirin and oral P2Y12 inhibitors, in the prevention and management of arterial thrombosis, has stimulated extensive pharmacodynamic studies and research into tailored antiplatelet regimens. Many different methodologies have been studied for monitoring antiplate...

journal_title：Seminars in thrombosis and hemostasis

authors： Orme R,Judge HM,Storey RF

更新日期：2017-04-01 00:00:00

abstract：:Three commercial prothrombin complex concentrates (PCC) were compared in vitro. Differences in the activities or contents, respectively, of the PCC factors FII, FVII, FIX, FX and the proteins C, S, and Z (antigen) in particular were found. Global tests of activated factors did not reveal marked differences between the...

journal_title：Seminars in thrombosis and hemostasis

authors： Römisch J,Bonik K,Müller HG

更新日期：1998-01-01 00:00:00